1.585USD+0.32%Mkt Cap: 244.49M USDP/E: —Last update: 2026-06-01
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting gr…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap244.49M USD
Enterprise Value132.58M USD
Revenue (TTM)46.88M USD
Gross Profit28.36M USD
Net Income (TTM)168.02M USD
Revenue/Share0.3830 USD
Last Price1.585 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS19249H1032
Valuation
P/E (Trailing)—
P/E (Forward)-1.56
PEG—
EV/EBITDA-0.81
EV/Revenue2.83
P/S5.23
P/B3.12
EPS (TTM)-1.42
EPS (Forward)-1.02
52W Range
0.710046% of range2.616
52W High2.616 USD
52W Low0.7100 USD
Profitability
Gross Margin67.24%
Oper. Margin-293.67%
EBITDA Margin0.00%
Profit Margin398.43%
ROE275.39%
ROA65.04%
Growth
Revenue Growth62.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.51M USD
CapEx (TTM)—
FCF Margin-57.72%
FCF Yield-11.07%
Net Debt-112.68M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity0.66
Current Ratio1.56
Quick Ratio1.43
Book Value/Sh0.5100 USD
Cash/Share1.083 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)7.800 USD
Target Range4.000 USD – 12.00 USD
# Analysts5
Ownership
Shares Out.154.25M
Float132.53M
Insiders18.54%
Institutions38.56%
Short Interest
Short Ratio20.7d
Short % Float18.78%
Short % Out.18.22%
Shares Short28.11M
Short (prev mo.)27.97M
Technical
SMA 501.710 (-7.3%)
SMA 2001.579 (+0.4%)
Beta1.02
S&P 52W Chg27.94%
Avg Vol (30d)1.22M
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)43.7
MACD-0.0403
MACD Signal-0.0408
MACD Hist.+0.0005
BB Upper1.905 USD
BB Middle1.669 USD
BB Lower1.433 USD
BB Width28.33%
ATR (14)0.1108 USD
Vol Ratio (20d)0.59x